317 related articles for article (PubMed ID: 28195349)
1. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.
Bruden DJT; McMahon BJ; Townshend-Bulson L; Gounder P; Gove J; Plotnik J; Homan C; Hewitt A; Barbour Y; Spradling PR; Simons BC; McArdle S; Bruce M
Hepatology; 2017 Jul; 66(1):37-45. PubMed ID: 28195349
[TBL] [Abstract][Full Text] [Related]
2. Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death.
McMahon BJ; Bruden D; Townshend-Bulson L; Simons B; Spradling P; Livingston S; Gove J; Hewitt A; Plotnik J; Homan C; Espera H; Negus S; Snowball M; Barbour Y; Bruce M; Gounder P
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):431-437.e2. PubMed ID: 27765729
[TBL] [Abstract][Full Text] [Related]
3. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
4. Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.
Ireland G; Simmons R; Hickman M; Harris R; Ramsay M; Sabin C; Mandal S
J Viral Hepat; 2020 Jan; 27(1):20-27. PubMed ID: 31505083
[TBL] [Abstract][Full Text] [Related]
5. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?
Goodgame B; Shaheen NJ; Galanko J; El-Serag HB
Am J Gastroenterol; 2003 Nov; 98(11):2535-42. PubMed ID: 14638360
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C.
Livingston SE; Deubner H; Bruden DL; McMahon BJ; Homan CE; Townshend-Bulson LJ; Bruce MG; Hennessy TW; Williams JL; Gretch DR
Can J Gastroenterol; 2010 Jul; 24(7):445-51. PubMed ID: 20652161
[TBL] [Abstract][Full Text] [Related]
7. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection.
McMahon BJ; Bruden D; Bruce MG; Livingston S; Christensen C; Homan C; Hennessy TW; Williams J; Sullivan D; Rosen HR; Gretch D
Gastroenterology; 2010 Mar; 138(3):922-31.e1. PubMed ID: 19909749
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
[TBL] [Abstract][Full Text] [Related]
9. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
10. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
[TBL] [Abstract][Full Text] [Related]
11. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index.
Nartey YA; Awuku YA; Agyei-Nkansah A; Duah A; Bampoh SA; Ayawin J; Asibey SO; Björkström NK; Ye W; Afihene MY; Roberts LR; Plymoth A
BMC Gastroenterol; 2020 Dec; 20(1):428. PubMed ID: 33357229
[TBL] [Abstract][Full Text] [Related]
13. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.
Limketkai BN; Mehta SH; Sutcliffe CG; Higgins YM; Torbenson MS; Brinkley SC; Moore RD; Thomas DL; Sulkowski MS
JAMA; 2012 Jul; 308(4):370-8. PubMed ID: 22820790
[TBL] [Abstract][Full Text] [Related]
14. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.
Smith DJ; Combellick J; Jordan AE; Hagan H
Int J Drug Policy; 2015 Oct; 26(10):911-21. PubMed ID: 26298331
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
Park H; Jiang X; Song HJ; Lo Re V; Childs-Kean LM; Lo-Ciganic WH; Cook RL; Nelson DR
Hepatology; 2021 Aug; 74(2):566-581. PubMed ID: 33544904
[TBL] [Abstract][Full Text] [Related]
17. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
18. SEN virus infection influences the pathological findings in liver but does not affect the incidence of hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis.
Moriyama M; Mikuni M; Matsumura H; Nakamura H; Oshiro S; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Tanaka N; Arakawa Y
Liver Int; 2005 Apr; 25(2):226-35. PubMed ID: 15780043
[TBL] [Abstract][Full Text] [Related]
19. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.
Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A
Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997
[TBL] [Abstract][Full Text] [Related]
20. The natural history of chronic hepatitis B: a retrospective study.
Wu GC; Zhou WP; Zhao YR; Guo SH; Wang ZY; Zou SB; Zhang QH; Ren H; Huang AL; Zhang DF
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):566-70. PubMed ID: 14627521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
